Eisai, Takeda Rely On U.S. Bioventures To Cover Patent Loss
This article was originally published in PharmAsia News
At least two major Japanese drug makers are counting on U.S. bioventures to provide them with products they need to replace income now produced by big-selling drugs. Eisai's takeover of MGI Pharma earlier this year gave it new cancer-fighting candidates, giving Eisai entry into an arm of the market considered to have high-growth potential. Takeda's more recent acquisition of Millennium Pharmaceuticals gave it access to cancer and anti-nausea drugs. Although their incomes are relatively small, the U.S. bioventures are expected to defray losses from Japanese drugs about to lose their patent protection. (Click here for more - a subscription may be required
You may also be interested in...
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
Breakthrough solutions based on new biological entities (ADCs and mAbs) are making hope real for patients with conditions of high unmet medical need. Byondis is developing therapies that target intractable cancers and autoimmune diseases and taking precision medicine to the next level.
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.